前列腺癌外照射放疗后活检长期结局的系统综述与荟萃分析
该系统综述与荟萃分析纳入22项研究(10项随机对照试验、12项队列研究),评估低至中危前列腺癌患者外照射放疗(EBRT)后活检阳性率及其与生化失败、远处转移和前列腺癌特异性死亡的关系。结果显示加权平均活检阳性率为32%(95%CI 25-39%,n=3017),活检阳性者生化失败、远处转移和前列腺癌特异性死亡的 odds 分别升高约10倍、3倍和5倍。
要点
- EBRT后活检阳性率加权平均为32%(95%CI 25-39%,n=3017)。
- 活检阳性者生化失败 odds 升高10倍(OR 10.3,95%CI 3.7-28.7,p<0.00001)。
- 活检阳性与远处转移和前列腺癌特异性死亡 odds 升高相关。
核心结论
- EBRT后活检阳性与较差预后相关,活检阳性率可作为比较EBRT与其他治疗方式的重要指标。
研究设计与样本
- 系统综述与荟萃分析,纳入截至2020年3月的22项研究(10项随机对照试验、12项队列研究),对象为低至中危前列腺癌接受EBRT后行活检的患者。
主要发现
- 22项研究加权平均活检阳性率为32%(95%CI 25-39%,n=3017)。
- 按研究方案行活检的研究中阳性率为35%(95%CI 21-38%,n=2450)。
- 符合2020 NCCN放疗指南的研究亚组阳性率为22%(95%CI 19-41%,n=832)。
- 活检阳性者生化失败 odds 升高10倍(OR 10.3,95%CI 3.7-28.7,p<0.00001)。
- 活检阳性者远处转移 odds 升高3倍(OR 3.1,95%CI 2.1-4.7,p<0.00001),前列腺癌特异性死亡 odds 升高5倍(OR 5.1,95%CI 2.6-10,p<0.00001)。
关键数值与推荐
- EBRT后≥2年行活检的阳性率作为主要结局指标。
- 22项研究中9项使用的剂量方案与2020 NCCN放疗指南一致。
临床怎么用
- EBRT后活检阳性提示局部复发风险高,可考虑加强随访或早期干预。
- 活检阳性率可用于不同治疗方式间的比较评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Biopsy after external beam radiotherapy (EBRT) for localised prostate cancer (PCa) is an infrequently used but potentially valuable technique to evaluate local recurrence and predict long-term outcomes. METHODS: We performed a meta-analysis of studies until March 2020 where a post-EBRT biopsy was performed on patients with low-to intermediate risk PCa, according to the Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA) statement. The primary outcome was the aggregate post-EBRT positive biopsy rate (≥2 years after EBRT) and the associated odds ratio (OR) of a positive biopsy on biochemical failure (BCF), distant metastasis-free survival (DMFS) and prostate cancer-specific mortality (PCSM). A sensitivity analysis was performed which examined biopsy rate as a function of post-EBRT biopsy protocol, PCa risk, ADT usage and radiation dose. RESULTS: A total of 22 studies were included, of which 10 were randomised controlled trials and 12 were cohort studies. Nine out of the 22 studies used dosing regimens consistent with the 2020 NCCN radiotherapy guidelines. The weighted-average positive biopsy rate across all 22 studies was 32% (95%-CI: 25-39%, n = 3017). In studies where post-treatment biopsy was part of the study protocol, the rate was 35% (95%-CI: 21-38%, n = 2450). In the subgroup of studies that conformed to the 2020 NCCN radiotherapy guidelines, this rate was 22% (95% CI: 19-41%, n = 832). Patients with positive biopsy had a 10-fold higher odds of developing BCF (OR of 10.3, 95%-CI: 3.7-28.7, p < 0.00001), 3-fold higher odds of developing distant metastasis (OR 3.1, 95%-CI: 2.1-4.7, p < 0.00001) and 5-fold higher odds of dying from their PCa (OR 5.1, 95%-CI: 2.6-10, p < 0.00001). CONCLUSION: A positive biopsy after EBRT is associated with a poor prognosis compared to a negative biopsy. The post-EBRT positive biopsy rate is an important measure which provides additional insight when comparing EBRT to other treatment modalities for PCa.
引用
- Singh S, Moore CM, Punwani S, et al. Long-term biopsy outcomes in prostate cancer patients treated with external beam radiotherapy: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2021. PMID: 33558660. doi:10.1038/s41391-021-00323-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。